AstraZeneca’s Fasenra OK’d for Self-Administration

October 15, 2019

The FDA approved the self-administration of AstraZeneca’s asthma biologic Fasenra (benralizumab) in a single-use, pre-filled auto-injector.

The add-on maintenance treatment can be used in severe eosinophilic asthma patients aged 12 and older. The medicine is designed to eliminate white blood cells that cause asthma in addition to helping manage symptoms.

The approval “means we can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor’s office,” an AZ spokesperson said.

View today's stories